Clene Inc. (CLNNW)

US — Healthcare Sector
Peers: RVPHW  ATNFW  CLNN  CLVRW  ARTLW 

Automate Your Wheel Strategy on CLNNW

With Tiblio's Option Bot, you can configure your own wheel strategy including CLNNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CLNNW
  • Rev/Share 0.0397
  • Book/Share -0.5635
  • PB -8.6951
  • Debt/Equity -4.2109
  • CurrentRatio 1.363
  • ROIC -1.4975

 

  • MktCap 44015475.0
  • FreeCF/Share -2.1824
  • PFCF -2.2854
  • PE -1.4874
  • Debt/Assets 0.8272
  • DivYield 0
  • ROE 6.2996

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Clene Inc. (CLNNW)

  • IPO Date
  • Website https://clene.com
  • Industry Biotechnology
  • CEO Mr. Robert Etherington MBA
  • Employees 75

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.